2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lung Neoplasms
2
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasm, Residual
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Hairy Cell
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Ependymoma
1
Carcinoma, Small Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma in Situ
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms
1
Interventions
Carboplatin
784
Pemetrexed
607
Cisplatin
545
Paclitaxel
491
pembrolizumab
464
Docetaxel
440
Gemcitabine
328
Erlotinib Hydrochloride
307
Radiotherapy
258
Nivolumab
244
Bevacizumab
233
osimertinib
178
Drug Therapy
164
durvalumab
157
atezolizumab
135
Gefitinib
134
Radiosurgery
133
Vinorelbine
111
Cetuximab
97
130-nm albumin-bound paclitaxel
94
Ipilimumab
86
Magnetic Resonance Spectroscopy
84
Taxes
79
Surgical Procedures, Operative
74
Afatinib
68
Albumin-Bound Paclitaxel
66
Specimen Handling
61
Etoposide
61
Cyclophosphamide
60
tislelizumab
59
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
Histamine Antagonists
×
Clear all
NCT06305754
2026-05-29
MK-2870-009
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
520 enrolled